In contrast to DMD, A1AT, and so on, genetic disease in which even minimalin vivo effectiveness in gene correction might produce gradual cumulative attenuation of pathology, there are dominant negative diseases, exemplified by the myotonic dystrophies, in which meaningful intervention would require gene editing in a large volume of tissue. This evidence concerns the gene DMD and hereditary disease.